1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Eversource Energy said it completed the sale of Aquarion Water Company to Aquarion Water Authority, a Connecticut public entity, for $2.4 billion in cash. The company expects an after-tax non-cash charge of about $115 million, or $0.31 per share, in the second quarter of 2026, and it revised its 2026 non-GAAP EPS guidance to $4.57 to $4.72 per share, which excludes Aquarion earnings going forward.
Total purchase price was $2.4 billion in cash; adjusted net equity proceeds of about $1.7 billion will be used to pay down Eversource debt.
After-tax non-cash charge of about $115 million, or $0.31 per share, expected in Q2 2026.
Revised 2026 non-GAAP guidance is $4.57 to $4.72 per share; the prior base-year midpoint cited is $4.65 per share.
Sale was approved by the Connecticut Public Utilities Regulatory Authority on March 25, 2026, after a definitive agreement signed January 27, 2025.
Talos Energy and an affiliate of Ridgewood Energy agreed on June 30, 2026 to buy oil and gas properties in the Gulf of America from Shell Offshore for an unadjusted $1.7 billion, with Talos's share at $850 million. Talos expects its final net cash consideration to be about $450 million to $500 million, and it plans to fund the deal with cash on hand and debt, which shareholders should weigh against the added production and reserves and the closing uncertainty.
Talos's share of the unadjusted purchase price is $850 million, with a $42.5 million deposit already in escrow and credited at closing.
Acquired assets include about 23 MMBoe of proved reserves, 10 MMBoe of probable reserves, and first quarter 2026 average production of about 16 MBoe/d (about 77% oil).
BP has a 30-day preferential right on the Na Kika interests; if exercised, Talos would acquire only the Coulomb field interest.
The credit agreement amendment raises the borrowing base from $700 million to $850 million ($800 million if BP exercises its right), effective upon closing, and the deal is expected to close by the end of 2026.
Oramed and Scilex Holding agreed on June 25, 2026 to a further extension of Scilex's payment obligations to Oramed under two senior notes. Scilex has paid $0.5 million so far, with $5 million due by July 31, 2026 and the remaining balance due by September 30, 2026. The filing also says Oramed's board approved amended bylaws effective June 25, 2026 that change stockholder written consent procedures.
Scilex owed approximately $29.5 million under the Tranche A Note and $6.7 million under the Tranche B Note as of June 30, 2026.
Oramed received $0.5 million from Scilex on June 25, 2026; $5 million is due on or before July 31, 2026, and the remaining balance on or before September 30, 2026.
If Scilex does not pay in full by September 30, 2026, the first $1.5 million received would be treated as a non-refundable extension fee, and Scilex has agreed to settle the remaining amount with Scilex common stock.
Fifth Amended and Restated Bylaws, effective June 25, 2026, revise record date procedures for written consent, eliminate a information requirement for record date requests, and set a 60-day delivery window for consents.
NIKE reported fiscal fourth-quarter 2026 revenue of $11.0 billion, down 1% on a reported basis, and diluted EPS of $0.72, up from $0.14 a year earlier. The EPS figure includes a $0.52 benefit from the expected recovery of IEEPA tariffs, and the filing gives no guidance for future periods. For full fiscal 2026, revenue was flat at $46.4 billion and diluted EPS fell 3% to $2.10.
Q4 revenue $11.0 billion, down 1% reported and down 4% currency-neutral; NIKE Direct down 7%
Q4 diluted EPS $0.72 vs. $0.14 a year earlier, including a $0.52 benefit from expected IEEPA tariff recovery
Fiscal 2026 revenue $46.4 billion, flat; net income $3.1 billion, down 3%; diluted EPS $2.10, down 3%
Fiscal 2026 dividends of $2.4 billion, up 5%; share repurchases of $123 million
On June 27, 2026, Martin Marietta agreed to acquire all equity interests in Lhoist North America from LNA Holding for $13.5 billion, consisting of $7 billion in cash and 10,953,543 newly issued Martin Marietta shares valued at $6.5 billion. After closing, LNA Holding is expected to hold about 15% of Martin Marietta's common stock, and the company has a $7.0 billion bridge loan commitment to fund the cash portion, so shareholders would face a larger share count and significant new borrowing if the deal closes.
Total consideration is $13.5 billion: $7 billion in cash plus 10,953,543 shares valued at $6.5 billion, based on the 15-day volume-weighted average price ending June 26, 2026
Closing requires expiration or termination of the Hart-Scott-Rodino waiting period and other regulatory approvals; long stop date is October 31, 2026, extendable to June 15, 2027
Martin Marietta would pay a $350 million termination fee if the deal ends under specified circumstances tied to failure to obtain regulatory clearances by the Extended Long Stop Date
A 364-day, $7.0 billion unsecured bridge facility from Goldman Sachs Bank USA and Goldman Sachs Lending Partners LLC is committed to finance the cash consideration
AeroVironment reported fiscal fourth-quarter 2026 revenue of $641.6 million, up 133% from $275.1 million, and net income of $63.2 million, or $1.25 per diluted share. For the full fiscal year, revenue rose 141% to $1,976.8 million, but the company posted a net loss of $265.1 million, or $5.40 per share, after a $240.7 million goodwill impairment. For fiscal 2027, the company expects revenue of $2.125 billion to $2.225 billion and net income of $8 million to $24 million.
Q4 fiscal 2026 revenue of $641.6 million; net income of $63.2 million, or $1.25 per diluted share, versus $16.7 million, or $0.59, a year earlier
Full-year fiscal 2026 net loss of $265.1 million, or $5.40 per diluted share, including a $240.7 million goodwill impairment
Fiscal 2027 guidance: revenue of $2.125 billion to $2.225 billion; net income of $8 million to $24 million; GAAP EPS of $0.16 to $0.48
Funded backlog of $1.2 billion as of April 30, 2026, versus $726.6 million a year earlier
Concentrix reported fiscal second-quarter 2026 results for the period ended May 31, 2026, with revenue up 1.9% to $2.46 billion, but operating income fell 35.7% to $95.4 million and non-GAAP diluted EPS fell 2.6% to $2.63. The company guided to non-GAAP diluted EPS of $10.83 to $11.18 for the full fiscal year, and expects adjusted free cash flow of $630 million to $650 million, while reporting no share repurchases in the quarter.
Revenue was $2,462.5 million, up 1.9% as reported and 0.6% in constant currency, versus $2,417.4 million a year earlier.
GAAP diluted EPS was $0.86, up from $0.63, while non-GAAP diluted EPS was $2.63, down from $2.70; non-GAAP operating income was $292.0 million, down 3.9%.
Acquisition-related, integration and restructuring expenses were $65.5 million in the quarter, versus $16.8 million a year earlier.
Third-quarter non-GAAP diluted EPS is expected at $2.65 to $2.77; the quarterly dividend of $0.36 per share is payable August 4, 2026.
Rocket Lab agreed on June 28, 2026 to acquire Iridium Communications in a cash and stock deal valued at $54 per Iridium share and an enterprise value of about $8.0 billion. Iridium holders would receive $27.00 in cash plus Rocket Lab stock, with the stock portion set by an exchange ratio that is subject to a collar between $67.50 and $112.50 per Rocket Lab share. The deal requires Iridium shareholder approval and regulatory clearances and is expected to close in mid-2027, and it is funded partly by a $3.6 billion bridge loan commitment.
Iridium holders receive $27.00 in cash plus Rocket Lab shares at an exchange ratio that is fixed at 0.4000 if the Rocket Lab price is $67.50 or below and at 0.2400 if it is $112.50 or above.
Iridium would pay Rocket Lab a $223.62 million termination fee in specified circumstances, including if its board withdraws support for the deal.
Rocket Lab has a 364-day senior secured bridge term loan commitment of $3.6 billion from Deutsche Bank and Wells Fargo.
The transaction is expected to close in mid-2027 and must be approved by a majority of Iridium's outstanding shares.
Honeywell completed the spin-off of its Aerospace business effective 12:01 a.m. New York time on June 29, 2026, making Honeywell Aerospace Inc. an independent public company that began regular-way trading on Nasdaq that day. The 8-K also covers agreements with Honeywell on separation, transition services, taxes, employee matters, intellectual property and trademarks, and supplemental unaudited quarterly results for 2024 and 2025 showing full-year 2025 net sales up but net income attributable to the company down.
Distribution: one share of Honeywell Aerospace common stock for every two Honeywell common shares held at the close of business on June 15, 2026; fractional shares were sold and cash paid instead.
Trading began on Nasdaq under HONA on June 29, 2026, with CUSIP 43849R105. Honeywell continues as Honeywell Technologies.
FY 2025 net sales were $17,404 million versus $15,445 million in FY 2024, while net income attributable to Honeywell Aerospace was $2,687 million versus $2,817 million.
Larimar Therapeutics said it has submitted the first module of a rolling Biologics License Application to the FDA for accelerated approval of nomlabofusp, after FDA meeting minutes said the existing data package appears sufficient for submission. The company also reported longer-term open label data, which showed improvements in some clinical measures alongside anaphylaxis in 10 of 43 patients, a safety finding shareholders should weigh.
First module of the rolling BLA submitted; remaining modules expected in the second half of 2026.
FDA meeting minutes say the existing data package appears sufficient for a BLA seeking accelerated approval; approval will be a matter of review.
Anaphylaxis occurred in 10 of 43 patients in the open label study, 9 of whom had prior exposure to nomlabofusp.
At 1 year, 100% (9/9) of participants had skin FXN levels above 50% of healthy volunteer mean; first patient dosing in a global Phase 3 study is expected in Q3 2026.
Verizon signed a transaction agreement on June 28, 2026 with BT Group and NewCo to combine its international wireline connectivity and managed network services business with BT's equivalent business, with each company holding 50% of NewCo. Verizon will also make a $625 million cash payment to NewCo, which will pass it to BT, and it expects a second-quarter 2026 estimated loss of $700 million to $800 million, plus severance and asset charges, that will weigh on reported results.
Transaction agreement signed June 28, 2026; closing is subject to customary regulatory approvals and closing conditions.
Verizon to pay $625 million in cash to NewCo; the value of each contributed business is subject to adjustment for cash, net working capital and indebtedness at closing.
Expected second-quarter 2026 estimated loss of $700 million to $800 million from classifying the Verizon Contributed Business as held for sale.
Severance charge of $350 million to $450 million and asset rationalization charges of $200 million to $300 million expected in the second quarter of 2026.
Applied Digital's subsidiary APLD Intermediate HoldCo entered into an incremental agreement that raises the revolving credit commitments under its May 29, 2026 credit agreement to $430.0 million, maturing May 28, 2029. The company also amended its Preferred Equity Purchase Agreement to lift the Series G Convertible Preferred Stock commitment from $1.59 billion to $2.0 billion, adding capacity for future equity issuance to investors.
Secured revolving credit facility increased to $430.0 million, maturing May 28, 2029, with up to $120.0 million more available for a total of $550.0 million
Credit facility priced at Term SOFR plus 2.25% or base rate plus 1.25%, guaranteed by the company and restricted subsidiaries
PEPA Series G Convertible Preferred Stock commitment raised from $1,590,000,000 to $2,000,000,000 under the Sixth Amendment dated June 26, 2026
H.B. Fuller and the board of Advanced Medical Solutions Group plc (AMS) agreed terms on a recommended cash offer, to be implemented through a UK court-sanctioned scheme of arrangement. The company has arranged bridge credit agreements of up to $2,086,713,188 (secured) and $917,000,000 (unsecured) to fund the deal and refinance debt, and expects completion by the end of calendar 2026, which would add new borrowings for shareholders to weigh against the strategic growth case.
AMS shareholders will receive 285 pence in cash per AMS share; the press release cites a total enterprise value of £715 million.
Secured Bridge Credit Agreement of up to $2,086,713,188 and Unsecured Bridge Credit Agreement of up to $917,000,000, both with Goldman Sachs Bank USA; loans would mature 364 days after closing.
Completion is expected by the end of calendar 2026, subject to AMS shareholder approval, High Court sanction, regulatory approvals, and a Long-Stop Date of June 25, 2027.
Company expects approximately $55 million in combined run-rate revenue and cost synergies by 2031.
Ark Restaurants said a New York court on June 18, 2026 granted it summary judgment on its breach of contract claim over the Bryant Park Grill lease and the related right of first lease for the Bryant Park Café, with money damages to be set at a later trial. The court also ruled against the company on ejectment and use and occupancy claims for the Café and The Porch, and the company says it will appeal the adverse portions, which would automatically stay eviction while the appeal is pending. The company says the dispute has had and is expected to continue to have a material adverse impact on its business and results.
June 18, 2026: court granted Ark summary judgment on breach of contract for the Bryant Park Grill lease and related right of first lease for the Bryant Park Café
Court did not grant specific performance and did not preclude the Landlord's ejectment claim; damages for the Grill to be determined at a future trial
Court ruled for the Landlord on ejectment, use and occupancy, and breach of contract for the Café and The Porch; the Landlord may seek use and occupancy damages at trial
Company intends to file a Notice of Appeal, which would stay eviction pending appeal; the court will set the amount of the required undertaking
Worthington Enterprises reported fourth-quarter fiscal 2026 results for the quarter ended May 31, 2026, with net sales up 17% to $371 million, driven largely by acquisitions, while adjusted EBITDA fell to $83.5 million from $85.1 million. For the full fiscal year, adjusted EBITDA rose 12% to $296 million and adjusted earnings per share rose 9% to $3.37. The company also disclosed a June 22, 2026 retention award of 25,000 performance shares each to its chief financial officer, general counsel and two segment presidents.
Q4 net sales were $371 million, up 17% from $318 million; organic growth was 3%.
Q4 adjusted EBITDA was $83.5 million versus $85.1 million a year earlier; adjusted earnings were $0.97 per share versus $1.06.
Full-year fiscal 2026 adjusted EBITDA rose 12% to $296 million; net debt was $278 million at May 31, 2026.
On June 22, 2026, the compensation committee awarded 25,000 performance shares each to Colin J. Souza (CFO), Patrick J. Kennedy, Steven M. Caravati and James R. Bowes.
REalloys Inc. closed a private placement on June 26, 2026, selling 7,017,540 shares of common stock at $14.25 per share for gross proceeds of approximately $100 million, before placement agent fees and offering expenses. The company will use the net proceeds for working capital and general corporate purposes, and it has agreed to register the resale of the shares, which adds new shares that could dilute existing shareholders.
Sold 7,017,540 shares of common stock at $14.25 per share, for gross proceeds of approximately $100 million
Closed on June 26, 2026, after the purchase agreement was signed on June 24, 2026
Clear Street LLC was the sole placement agent; net proceeds will go to working capital and general corporate purposes
Company agreed to file a registration statement to register the resale of the shares
Apogee Enterprises reported first-quarter fiscal 2027 results, with net sales down 1.1% to $342.7 million on lower volume, while diluted earnings per share swung to $0.54 from a loss of $0.13 a year earlier. The company reaffirmed its fiscal 2027 guidance and said the pending Kalwall acquisition remains on track for an early July close.
Net sales were $342.7 million, down 1.1% from $346.6 million, driven by lower volume partly offset by favorable pricing.
Diluted EPS was $0.54 versus a loss of $0.13; adjusted diluted EPS was $0.57 versus $0.56.
Adjusted EBITDA fell 6.6% to $32.1 million, and adjusted EBITDA margin declined to 9.4% from 9.9%.
Fiscal 2027 guidance was reaffirmed: net sales of $1.38 billion to $1.43 billion and adjusted diluted EPS of $2.70 to $3.25, excluding Kalwall.
Cineverse reported fourth-quarter revenue of $26.0 million, up 67% from a year earlier, largely from the Giant Worldwide and IndiCue acquisitions, which contributed $11.6 million in their first partial quarter. For the full fiscal year ended March 31, 2026, revenue fell 16% to $65.7 million and the company posted a net loss attributable to common stockholders of $9.2 million, or $0.49 per diluted share, compared with net income of $3.2 million, or $0.16 per diluted share, a year earlier. The company reaffirmed its fiscal 2027 guidance of $115 million to $120 million in revenue and $10 million to $20 million in Adjusted EBITDA.
Q4 FY 2026 revenue of $26.0 million versus $15.6 million in Q4 FY 2025; Q4 net income attributable to common stockholders of $1.1 million, or $0.05 per diluted share
FY 2026 revenue of $65.7 million versus $78.2 million, with the decline tied to the prior-year Terrifier 3 comparison
FY 2026 net loss attributable to common stockholders of $(9.2) million, or $(0.49) per diluted share, versus net income of $3.2 million in FY 2025; Adjusted EBITDA of $(3.4) million versus $13.9 million
Fiscal 2027 guidance reaffirmed: revenue of $115 million to $120 million and Adjusted EBITDA of $10 million to $20 million; cash and cash equivalents were $3.4 million as of March 31, 2026
onsemi agreed on June 25, 2026 to acquire Synaptics in an all-stock transaction with a total enterprise value of about $7 billion, using a fixed exchange ratio of 1.350 onsemi shares for each Synaptics share. Synaptics stockholders would own about 12% of the combined company, so onsemi holders would be diluted, while onsemi expects the deal to be accretive to non-GAAP EPS within 18 months of closing. Closing is expected in mid-2027, subject to a Synaptics stockholder vote and regulatory approvals, and both companies reiterated their prior financial outlooks.
Fixed exchange ratio of 1.350 onsemi shares per Synaptics share; Synaptics holders to own about 12% of the combined company on a pro forma basis.
Total enterprise value of about $7 billion, an approximately 19% premium to the 10-trading-day volume weighted average closing prices.
onsemi expects $200 million in annual synergies and non-GAAP EPS accretion within 18 months of closing.
Closing expected in mid-2027; the merger agreement can be terminated if not completed by June 25, 2027, subject to extensions.
FedEx Freight reported fourth-quarter fiscal 2026 revenue of $2.4 billion, up 4.8%, but operating income of $158 million fell 66.9%, with spin-off costs and higher wage rates cited as factors. The company also introduced standalone guidance for a seven-month transition period ending December 31, 2026, after its June 1, 2026 spin-off from FedEx Corporation and a change in its fiscal year-end.
Q4 fiscal 2026: revenue $2.4 billion (up 4.8%); operating income $158 million (down 66.9%); adjusted operating income $363 million (down 23.9%)
Full fiscal 2026: revenue $8.8 billion (down 1.1%); operating income $616 million (down 58.6%)
Transition period guidance: operating income $475 million to $515 million versus $394 million a year earlier; diluted EPS $2.40 to $2.60 after spin-off costs, excluding MTM retirement plan adjustments that the company cannot forecast
HeartCore Enterprises agreed on June 22, 2026 to sell its entire 51% stake in Sigmaways, Inc. and $2.19 million in Sigmaways promissory notes to Semaphore Technologies, with the closing on the same day. The up-to-$650,000 price consists of a $1,000 cash payment at closing and an earn-out of up to $649,000 tied to Sigmaways' future gross revenue, and HeartCore also gave up a $350,000 SAFE note as part of a mutual release. The company says the sale removes a loss-making subsidiary with a shareholders' deficit of about $3.6 million (unaudited) as of March 31, 2026 from its consolidated results.
Sold 229,500 shares (51% ownership) of Sigmaways and $2.19 million in promissory notes to Semaphore Technologies; closed June 22, 2026.
Purchase price up to $650,000: $1,000 cash at closing plus an earn-out of up to $649,000.
Earn-out equals 10% of Sigmaways gross revenue above $5,500,000 over the 12 months after closing, payable within 10 days after that period.
Sigmaways had a shareholders' deficit of about $3.6 million (unaudited) as of March 31, 2026; HeartCore contributed a $350,000 SAFE note from Heart-Tech Health, Inc. in a mutual release.
McCormick reported fiscal second-quarter 2026 results for the period ended May 31, 2026, with net sales up 16.7% and adjusted earnings per share up to $0.80 from $0.69. GAAP earnings per share fell to $0.56 from $0.65 because special charges, including transaction and integration costs, reduced earnings by $0.24 per share. The company reaffirmed its fiscal 2026 outlook while it advances integration planning for the proposed Unilever Foods combination.
Net sales rose 16.7% to a total that included a 2.7% favorable currency impact; organic sales growth was 1.7%.
Adjusted operating income was $336.4 million, up from $258.6 million; reported operating income was $276.4 million, up from $245.8 million.
Reported EPS was $0.56 versus $0.65 a year earlier; special charges lowered diluted EPS by $0.24.
The company reaffirmed fiscal 2026 adjusted operating income growth of 16% to 20% and adjusted EPS of $3.05 to $3.13.
TD SYNNEX reported record fiscal second-quarter 2026 results, with revenue up 31.0% year over year and GAAP diluted EPS of $4.15, up 87.8%. The company also declared a quarterly dividend of $0.48 per share, up 9% year over year. Free cash flow was negative $332 million in the quarter, and the company's outlook for the third quarter calls for revenue of $18.2 billion to $19.0 billion, with GAAP diluted EPS of $3.40 to $3.90.
Q2 fiscal 2026 revenue of $19.6 billion, up 31.0%; GAAP diluted EPS of $4.15 vs. $2.21, and non-GAAP diluted EPS of $4.85 vs. $2.99
Q2 operating cash flow was negative $265.6 million; free cash flow was negative $332.4 million
Q3 fiscal 2026 outlook: revenue $18.2 billion to $19.0 billion; GAAP diluted EPS $3.40 to $3.90; non-GAAP diluted EPS $4.25 to $4.75
Quarterly dividend of $0.48 per share payable July 31, 2026, to holders of record as of July 17, 2026
Worthington Steel reported fiscal fourth-quarter 2026 results (three months ended May 31, 2026) with net sales up 12% to $929.2 million but a net loss attributable to controlling interest of $48.7 million, compared with earnings of $55.7 million a year earlier. The loss was driven mainly by $94.5 million of goodwill and long-lived asset impairments in the Electrical Steel unit. The company also issued a corrected results release and said it completed its majority acquisition of Klöckner & Co SE on June 3, 2026.
Net sales rose to $929.2 million from $832.9 million; diluted loss per share was $0.98 versus earnings of $1.10
Operating loss of $57.6 million compared with operating income of $66.4 million, including $94.5 million of impairments
Adjusted diluted EPS was $0.74 versus $1.05 a year earlier
Kloeckner acquisition settled June 3, 2026, giving the company about 62% of Kloeckner's outstanding shares; quarterly dividend of $0.16 payable September 29, 2026
Elastic N.V. committed on June 23, 2026 to a plan to reduce its workforce by about 7%, with total non-recurring cash charges of approximately $22 million to $25 million, mostly employee severance, and most of those charges expected in the first quarter of fiscal 2027. Chief Product Officer Ken Exner also resigned, with his last day set for July 17, 2026, and senior engineering leaders will now report to CEO Ashutosh Kulkarni. The filing says total headcount is still expected to grow this fiscal year.
Workforce reduction of approximately 7%; implementation expected to be substantially complete by the end of fiscal Q3 2027
Non-recurring cash charges of approximately $22 million to $25 million, mostly severance and termination benefits
Chief Product Officer Ken Exner resigns effective July 17, 2026; he is leaving for another opportunity, not over a disagreement
Engineering leaders for Elasticsearch and Platform Group and Observability and Security Group will report to CEO Ashutosh Kulkarni
On June 24, 2026, Passage Bio agreed to merge with Remix Therapeutics in an all-stock deal, with the combined company to operate as Remix Therapeutics under the ticker RMTX. Passage shareholders are expected to own about 7% of the combined company, subject to adjustment based on Passage's net cash at closing, and will receive contingent value rights tied to milestones from its out-licensed pediatric gene therapy assets. Closing requires stockholder approvals and a concurrent Remix financing of at least $100 million, and is expected in the fourth quarter of 2026.
Remix has been ascribed an aggregate equity value of $226 million; Passage's equity value is expected to be about $20 million, subject to net cash adjustment.
Remix will complete a concurrent financing of at least $100 million immediately before the merger closes.
Termination payments: $17.5 million from Remix to Passage, or $1.548 million from Passage to Remix, in specified circumstances.
Peter Smith, Ph.D., Remix's co-founder and CEO, will become CEO of the combined company; the merger outside date is December 24, 2026.
MillerKnoll reported fourth-quarter and full fiscal 2026 results for the period ended May 30, 2026, with net sales up 4.4% to $1.004 billion and GAAP diluted EPS of $0.34, compared with a loss of $0.84 a year earlier. Adjusted diluted EPS fell to $0.55 from $0.60, orders declined 6.3%, and Jeff Stutz, Chief Operating Officer, is stepping into the interim CEO role. The company also gave first-quarter and full fiscal 2027 adjusted EPS outlooks of $0.33 to $0.39 and $1.85 to $2.15.
Q4 net sales of $1.004 billion, up 4.4% as reported; orders of $971.5 million, down 6.3%
Q4 GAAP diluted EPS of $0.34 vs. a loss of $0.84 a year earlier; adjusted diluted EPS of $0.55 vs. $0.60
Q1 FY2027 adjusted EPS outlook of $0.33 to $0.39; full year FY2027 outlook of $1.85 to $2.15
Jeff Stutz named incoming interim CEO; company recorded $2.6 million in CEO transition costs in Q4
Crown Crafts reported fourth-quarter fiscal 2026 net income of $0.3 million, or $0.03 per diluted share, compared with a net loss of $10.8 million a year earlier, which included a $13.8 million goodwill impairment charge. Net sales fell to $22.4 million from $23.2 million, and for the full year, net sales were $82.3 million compared with $87.3 million.
Q4 fiscal 2026 net sales $22.4 million vs. $23.2 million; gross margin 22.9% vs. 18.3%
Q4 net income $0.3 million ($0.03 per diluted share) vs. net loss $10.8 million ($1.04 per share) in the prior-year quarter
Full-year fiscal 2026 net income $1.8 million ($0.17 per diluted share) vs. net loss $9.4 million; quarterly dividend of $0.08 per share payable July 2, 2026
Worthington Enterprises reported fiscal 2026 fourth-quarter net sales of $371.5 million, up 17%, and GAAP diluted EPS of $0.97 versus $0.08 a year earlier, a period that included a $50.8 million impairment. Adjusted diluted EPS fell to $0.97 from $1.06, while full-year net sales rose 20% to $1.4 billion and adjusted diluted EPS rose to $3.37 from $3.09. The company also declared a $0.20 quarterly dividend and appointed W. Bradley Southern as a director.
Q4 net sales $371.5 million, up 17%; GAAP diluted EPS $0.97 vs $0.08; adjusted diluted EPS $0.97 vs $1.06
Full-year net sales $1.4 billion, up 20%; GAAP diluted EPS $3.14 vs $1.92; adjusted diluted EPS $3.37 vs $3.09
Quarterly dividend of $0.20 per share, payable September 29, 2026, to holders of record on September 15, 2026
Former Louisiana-Pacific CEO W. Bradley Southern appointed director; board plans to reduce authorized directors to 11 as three directors retire
FedEx reported fiscal fourth-quarter revenue of $25.0 billion, up from $22.2 billion a year earlier, and adjusted diluted EPS of $6.31, up from $6.07. GAAP diluted EPS fell to $6.60 from $6.88, mainly due to FedEx Freight spin-off costs, business optimization costs and other adjustments. The filing also completed the June 1, 2026 FedEx Freight spin-off and gave a calendar 2026 outlook of about 11% revenue growth and GAAP diluted EPS of $16.55 to $17.75.
Q4 revenue $25.0 billion vs. $22.2 billion a year earlier; GAAP operating income $1.55 billion vs. $1.79 billion
Q4 adjusted diluted EPS $6.31 vs. $6.07; GAAP diluted EPS $6.60 vs. $6.88
Calendar 2026 forecast: revenue growth about 11%, GAAP diluted EPS $16.55 to $17.75, adjusted $16.90 to $18.10; plans to repurchase up to $1 billion of shares
Boundless Bio agreed on June 22, 2026 to an all-stock merger with privately held Serapha Bio, a clinical-stage company developing an in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency. Boundless stockholders are expected to own about 3.69% of the combined company, and the company's CEO, Zachary Hornby, steps down effective July 1, 2026, which affects shareholders' stake and the company's management.
Merger agreement dated June 22, 2026; the combined company is expected to operate as Serapha Bio and trade as AATD, subject to Nasdaq approval
Pre-merger Boundless holders expected to own about 3.69% and Serapha holders about 96.31% of the combined company, fully diluted
Boundless may pay a pre-closing cash dividend; the press release says about $44 to $48 million, and the press release states the BBI-940 program will not be advanced
CEO Zachary Hornby steps down July 1, 2026; Chief Legal Officer Jessica Oien to serve as principal executive officer; closing expected in Q4 2026
MapLight Therapeutics reported topline results from its Phase 2 IRIS trial of ML-004 in autism spectrum disorder, announced June 22, 2026. The study did not meet its primary endpoint on social communication deficits, but a prespecified analysis in adolescents with moderate-to-severe irritability showed improvement over placebo, and the company plans to meet with the FDA to determine the development path.
Primary endpoint (ABI-SC social communication domain) was not met; no statistical separation from placebo on that measure.
In adolescents with baseline ABC-I score of 16 or higher (N=20), care-partner-reported ABC-I improved over placebo: effect size 1.33, nominal p=0.013.
Two adolescents (3.9%) on ML-004 discontinued due to an adverse event versus none on placebo; no severe or serious adverse events occurred with ML-004.
The company expects to engage the FDA in an End-of-Phase 2 meeting; the trial enrolled 161 participants, including 102 adolescents.
HawkEye 360 reported first quarter 2026 results for the period ended March 31, with record revenue of $49.8 million, up 116.5% from $23.0 million a year earlier. The net loss widened to $9.0 million from $1.6 million, and backlog fell to $285.0 million from $302.7 million at year-end 2025. The company also completed an initial public offering in May 2026 that generated $435.9 million in net proceeds, and it will provide its 2026 outlook with its second quarter results.
Total revenue was $49.8 million, up 116.5% from $23.0 million in the prior-year period.
Net loss was $9.0 million, compared with $1.6 million a year earlier; adjusted EBITDA, a non-GAAP measure, was $7.4 million.
Backlog was $285.0 million at March 31, 2026, down from $302.7 million at December 31, 2025.
The IPO sold 18.4 million shares at $26.00 per share, generating net proceeds of $435.9 million.
At its June 16, 2026 annual meeting, Match Group stockholders did not approve, on an advisory basis, the pay of the named executive officers for fiscal 2025, with more votes against than in favor. Stockholders also approved an amendment to the 2024 stock and incentive plan, adding 6,250,000 shares, and elected four directors, so shareholders should note the rejected pay vote as a signal of concern about executive compensation.
Say-on-pay proposal not approved: 85,252,504 votes for, 114,012,022 against, 93,135 abstaining.
Second Amended and Restated 2024 Stock and Annual Incentive Plan approved: 133,116,903 for, 66,173,398 against; adds 6,250,000 shares and extends the term to the tenth anniversary of the 2026 annual meeting.
Ann L. McDaniel received 34,663,099 votes against, the largest opposition among the four director nominees, all of whom were elected to one-year terms.
Stockholders ratified Ernst & Young LLP as independent registered accounting firm for fiscal 2026 with 199,786,113 votes in favor.
Accenture reported third-quarter fiscal 2026 revenue of $18.72 billion, up 6% in U.S. dollars and 3% in local currency, and diluted EPS of $3.80, up 9%. It now expects full-year revenue growth of 3% to 4% in local currency, down from 3% to 5% in March, and raised the low end of its GAAP diluted EPS range to $13.38 to $13.50. Profit grew, but new bookings fell 2% and the revenue outlook was lowered.
Q3 FY26 revenue $18.72 billion, up 6% in U.S. dollars and 3% in local currency; diluted EPS $3.80 versus $3.49 a year earlier
Full-year FY26 local-currency revenue growth now 3% to 4%, versus 3% to 5% as of March 19, 2026
Full-year GAAP diluted EPS now $13.38 to $13.50, versus $13.25 to $13.50 previously
New bookings $19.32 billion, down 2% in U.S. dollars; free cash flow $3.6 billion; quarterly dividend of $1.63 per share payable August 14, 2026
CarMax reported first quarter fiscal 2027 results for the period ended May 31, 2026, with net revenues up 6.2% to $8.0 billion while net earnings fell 11.8% to $185.6 million. The company also disclosed a $500 million term loan from MUFG Bank maturing June 15, 2029, and said it made no share repurchases in the quarter.
Net revenues rose 6.2% to $8.0 billion; diluted EPS was $1.31 versus $1.38 a year earlier
Gross profit fell 4.4% to $854.4 million; SG&A expenses decreased 3.7% to $635.2 million
No shares were repurchased in the quarter; $1.31 billion remained under the authorization as of May 31, 2026
On June 15, 2026, CarMax Auto Superstores borrowed $500 million under a term loan maturing June 15, 2029, with proceeds used to pay down revolving credit borrowings
California Resources announced a proposed private offering of $550 million of senior unsecured notes due 2035, with proceeds plus revolver borrowings and/or cash on hand to redeem all $550 million of its 8.250% notes due 2029 at 104.125% plus accrued interest. The filing's exhibits also show a first-quarter 2026 net loss of $711 million and negative free cash flow of $32 million, so shareholders face a refinancing alongside a weak quarter.
Proposed offering of $550 million senior unsecured notes due 2035, subject to market and other conditions, sold to qualified institutional buyers and non-U.S. persons
Redemption of all $550 million of 8.250% senior notes due 2029 at 104.125% plus accrued and unpaid interest; the redemption is conditioned on completion of the offering
Excerpts show a net loss of $711 million and free cash flow of negative $32 million for the three months ended March 31, 2026; cash and equivalents were $32 million as of May 31, 2026 with no revolver balance
Robinhood Markets announced a reduction in force affecting approximately 10% of its full-time employees, plus closure of a small number of open roles. The company estimates about $20 million in cash severance and benefits costs and about $8 million in share-based compensation, with the accrual expected in the second quarter of 2026. The company says the move is taken from a position of business strength, citing June month-to-date average daily trading volumes at record levels.
Reduction in force affects approximately 10% of full-time employees, plus closure of a small number of open roles
Estimated cash restructuring charges of approximately $20 million for employee severance and benefits
Estimated approximately $8 million in share-based compensation charges
Accrual expected to be recognized in the second quarter of 2026
NextEra Energy filed unaudited pro forma financial statements for its proposed merger with Dominion Energy, which was agreed on May 15, 2026. The filing estimates total merger consideration of $62.4 billion, based on NEE's $84.84 closing price on June 11, 2026, and shows pro forma earnings per share below NEE's historical figures, though pro forma net income is higher. The deal still needs shareholder approvals and several regulatory approvals before closing.
Each Dominion Energy share would receive 0.8138 NEE shares plus a pro rata share of $360 million in cash.
Pro forma basic EPS for the three months ended March 31, 2026 was $0.92, versus NEE's historical $1.05.
Pro forma basic EPS for 2025 was $3.20, versus NEE's historical $3.31; pro forma 2025 operating revenues were $42.9 billion.
Closing requires approval by both companies' shareholders and approvals including HSR, FERC, NRC, and the Virginia, North Carolina and South Carolina regulators.
Supermicro agreed on June 10 and 11, 2026 to sell common stock and mandatory convertible preferred stock, with the company saying the proceeds will help fund components for approximately $39 billion of AI server orders from more than 20 customers. The common stock priced at $27.50 per share and the depositary shares at $50 each, and the company also set up a separate at-the-market program of up to $1.25 billion. The offerings add dilution for existing common shareholders, and the filing contains no revenue, profit or guidance figures.
Common stock: 45,454,545 shares at $27.50 per share, with underwriters holding a 30-day option on 6,818,181 more shares; closing expected June 12, 2026.
Depositary shares: 75,000,000 at $50 each, each representing a 1/20th interest in 7.0% series A mandatory convertible preferred stock; closing expected June 15, 2026.
At-the-market program: up to $1.25 billion of common stock through J.P. Morgan, Goldman Sachs and Citigroup, with sales not expected to start until the third quarter of 2026 and commissions of up to 1.0%.
Credit agreement Amendment No. 2, dated June 10, 2026, allows additional distributions on certain preferred stock, subject to a pro forma fixed charge coverage ratio of at least 2.00:1.00.
RH reported first quarter 2026 results for the period ended May 2, 2026, with net revenues down 1.7% to $800.3 million and a net loss of $13.7 million, compared with net income of $8.0 million a year earlier. The company raised its full-year 2026 outlook, which matters to shareholders because it signals management expects revenue growth of 4.5% to 8.0% for the year despite the weaker quarter.
Q1 net loss of $13.7 million, or $0.73 per diluted share, versus net income of $8.0 million, or $0.40 per diluted share, in the prior-year quarter
Q1 adjusted EBITDA of $56.9 million, with an adjusted EBITDA margin of 7.1%
Raised fiscal 2026 outlook: revenue growth of 4.5% to 8.0% and adjusted EBITDA margin of 14.2% to 16.0%
Second quarter 2026 outlook: revenue growth of 0.5% to 2.5% and adjusted EBITDA margin of 11.5% to 13.0%
On June 5, 2026, Factorial Inc. merged into Cartesian Growth Corporation III, which was renamed Factorial Energy, Inc. and listed on Nasdaq under FAC. The filing says the deal brought approximately $112.1 million in gross proceeds before transaction expenses, and management said this capital alleviated the substantial doubt about the company's ability to continue as a going concern. Shareholders face a large share overhang, since about 80.6 million shares, or 88.1% of outstanding Series A common stock, are subject to registration rights, and the company reported a Q1 2026 net loss of $8.6 million.
Business combination closed June 5, 2026; Cartesian Growth Corporation III renamed Factorial Energy, Inc., trading on Nasdaq as FAC
Gross proceeds of approximately $112.1 million from the de-SPAC transaction and PIPE, before transaction expenses
About 80.6 million shares, or 88.1% of outstanding PubCo Series A common stock, subject to registration rights after closing
Q1 2026 net loss of $8.6 million, down from $12.9 million a year earlier; cash and cash equivalents of $25.4 million at March 31, 2026
RadNet entered into an amendment to its credit agreement that adds a $250.0 million incremental term loan, maturing April 18, 2031, and lowers the interest rate on its term loan and $282 million revolving credit facility by 0.25%. The company plans to use the proceeds for acquisitions, organic expansion, health system partnerships and general corporate purposes, while quarterly principal payments rise to approximately $3.1 million from approximately $2.4 million.
$250.0 million incremental term loan added to the existing term loan, maturing April 18, 2031
Term loan rate reduced 0.25% to Term SOFR plus 2.00% or Alternate Base Rate plus 1.00%, at the company's election
Quarterly principal payments rise to approximately $3.1 million from approximately $2.4 million
Revolving credit facility of $282 million, currently undrawn, had its rate reduced 0.25%
Oxford Industries reported first-quarter fiscal 2026 net sales of $391 million, down from $393 million a year earlier, and GAAP earnings per share of $1.00, down from $1.70. The company narrowed its full-year sales forecast by lowering the top of the range and raised the low end of its adjusted EPS forecast, so shareholders face weaker sales expectations but a narrower profit outlook.
Q1 fiscal 2026 net sales were $391 million versus $393 million; Lilly Pulitzer sales fell 8.8% and Johnny Was fell 12.9%.
GAAP EPS was $1.00 versus $1.70; adjusted EPS was $1.39 versus $1.82, and tariffs added $11 million, or $0.55 per share.
Full-year fiscal 2026 net sales are now expected at $1.475 billion to $1.505 billion, with the top end lowered.
Adjusted EPS guidance is $2.30 to $2.70, with the low end raised; the board declared a $0.70 quarterly dividend payable July 31, 2026.
On June 8, 2026, Ingredion agreed with Tate & Lyle's board on a recommended all-cash acquisition of Tate & Lyle at 595 pence per share, with cash consideration of about £2.7 billion (about $3.6 billion) and an implied enterprise value of about $5.0 billion. Ingredion plans to fund the deal with existing cash, new debt and, if needed, a 364-day bridge loan, and expects pro forma net leverage of about 3.0x net debt-to-adjusted EBITDA at completion. The deal is expected to close in the second half of 2027, subject to Tate & Lyle shareholder and court approval and antitrust conditions, and Ingredion expects it to be adjusted EPS accretive in the first year.
Tate & Lyle shareholders would receive 595 pence in cash per share, about a 59% premium to the May 13, 2026 closing price.
Cash consideration is about £2.7 billion (about $3.6 billion); implied enterprise value is about £3.7 billion ($5.0 billion).
Ingredion expects pro forma net leverage of about 3.0x at completion and about 2.5x within about 18 months.
Expected run-rate net cost synergies of about $130 million by the end of 2030, against one-time costs of about $175 million.
Lakeland Industries reported fiscal first quarter 2027 results for the period ended April 30, 2026. Net sales rose 1.4% to $47.4 million and net income was $0.4 million, compared with a net loss of $3.9 million a year earlier, but the profit swing reflects a $6.5 million gain on the sale of HPFR and HiViz product lines, while gross profit fell 4.9%.
Net sales were $47.4 million, up $0.7 million or 1.4% from $46.7 million in Q1 FY26.
Gross profit was $14.9 million, down $0.8 million or 4.9% from $15.6 million.
Net income was $0.4 million versus a net loss of $3.9 million, and the reconciliation includes a $6.5 million gain on sale of certain assets recorded in March 2026.
Adjusted EBITDA excluding FX was $1.1 million, compared with $0.6 million; borrowings under the revolving credit facility were $23.8 million as of April 30, 2026.
Cracker Barrel reported fiscal third-quarter 2026 revenue of $797.4 million, down 2.9% from a year earlier, and GAAP diluted earnings of $1.90 per share, which include a $47.4 million litigation settlement benefit. Excluding non-GAAP adjustments, adjusted diluted earnings were $0.29 per share versus $0.58 a year earlier, and adjusted EBITDA was $40.3 million versus $48.1 million. The company raised its fiscal 2026 revenue and adjusted EBITDA outlook, which is the main positive for shareholders.
Q3 total revenue $797.4 million, down 2.9%; comparable store restaurant sales down 2.6%
GAAP diluted EPS $1.90 vs $0.56; adjusted diluted EPS $0.29 vs $0.58
Fiscal 2026 adjusted EBITDA outlook raised to $120 million to $125 million from $85 million to $100 million
Fiscal 2026 revenue outlook raised to $3.27 billion to $3.30 billion from $3.24 billion to $3.27 billion
Perma-Pipe reported first-quarter fiscal 2026 results for the quarter ended April 30, 2026. Net sales rose 7.5% to $50.3 million, but gross profit fell to $14.6 million from $16.7 million, and net income attributable to common stock fell to $1.8 million from $5.0 million, which management attributed partly to Middle East project delays and start-up costs. Management still expects revenue and net income growth for fiscal 2026 compared with fiscal 2025.
Net sales were $50.3 million, up from $46.7 million a year earlier, driven by higher volumes in North America and MENA.
Net income attributable to common stock was $1.8 million, versus $5.0 million; diluted EPS was $0.22, versus $0.61.
Backlog reached $136.5 million at April 30, 2026, up about 12% from $121.6 million at January 31, 2026.
Management said no projects have been cancelled and still expects revenue and net income growth for fiscal 2026.
Titan Machinery reported fiscal first-quarter 2027 results for the three months ended April 30, 2026. Revenue fell to $522.4 million from $594.3 million, while the net loss narrowed to $12.6 million, or $0.55 per diluted share, from $13.2 million, or $0.58 per share. The company reaffirmed its fiscal 2027 modeling assumptions, which include an adjusted diluted loss per share of ($1.25) to ($1.75), so shareholders see a smaller loss against weaker sales and continued expected losses for the year.
Revenue was $522.4 million versus $594.3 million a year earlier; Europe revenue fell 35.6% and Agriculture revenue fell 10.4%.
Net loss was $12.6 million, or $0.55 per diluted share, compared with a net loss of $13.2 million, or $0.58 per share.
Gross profit margin rose to 17.1% from 15.3%, while adjusted EBITDA was $1.0 million versus $2.6 million.
Fiscal 2027 guidance was reaffirmed, with adjusted diluted loss per share expected at ($1.25) to ($1.75); net cash used for operating activities was $23.1 million.
J.M. Smucker reported fourth-quarter fiscal 2026 net sales of $2.3 billion, up 6%, and adjusted earnings per share of $2.77, up 20%. For the full fiscal year, adjusted EPS fell 10% to $9.15 and the company posted a net loss of $1.30 per diluted share, while it guided fiscal 2027 net sales down 3.0% to 4.0% and adjusted EPS of $9.75 to $10.25.
Q4 net sales $2.3 billion (about $2,268.1 million), up 6%; adjusted EPS $2.77 vs. $2.31 a year earlier.
Q4 GAAP net income $3.64 per diluted share, compared with a net loss of $6.85 in the prior-year quarter, which included $867.3 million of goodwill impairment charges.
Fiscal 2026 net sales $9.1 billion, up 4%; net loss of $1.30 per diluted share; adjusted EPS $9.15, down 10%.
Fiscal 2027 outlook: net sales down 3.0% to 4.0%, adjusted EPS $9.75 to $10.25, free cash flow about $1.0 billion.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.